Affordable Access

deepdyve-link
Publisher Website

Dengue Virus and Its Inhibitors: A Brief Review.

Authors
  • Tian, Yu-Shi1
  • Zhou, Yi1
  • Takagi, Tatsuya1
  • Kameoka, Masanori2
  • Kawashita, Norihito1, 3
  • 1 Graduate School of Pharmaceutical Sciences, Osaka University.
  • 2 Department of International Health, Kobe University Graduate School of Health Sciences.
  • 3 Faculty of Sciences and Engineering, Kindai University.
Type
Published Article
Journal
Chemical and Pharmaceutical Bulletin
Publisher
Pharmaceutical Society of Japan
Publication Date
Jan 01, 2018
Volume
66
Issue
3
Pages
191–206
Identifiers
DOI: 10.1248/cpb.c17-00794
PMID: 29491253
Source
Medline
Keywords
License
Unknown

Abstract

The global occurrence of viral infectious diseases poses a significant threat to human health. Dengue virus (DENV) infection is one of the most noteworthy of these infections. According to a WHO survey, approximately 400 million people are infected annually; symptoms deteriorate in approximately one percent of cases. Numerous foundational and clinical investigations on viral epidemiology, structure and function analysis, infection source and route, therapeutic targets, vaccines, and therapeutic drugs have been conducted by both academic and industrial researchers. At present, CYD-TDV or Dengvaxia® is the only approved vaccine, but potent inhibitors are currently under development. In this review, an overview of the viral life circle and the history of DENVs is presented, and the most recently reported antiviral candidates and newly discovered promising targets are focused and summarized. We believe that these successes and failures have enabled progress in anti-DENV drug discovery and hope that our review will stimulate further innovation in this area.

Report this publication

Statistics

Seen <100 times